Saturday 17 October 2026
Export SVA’s income statement to Excel — free account
Sinovac Biotech, Ltd.
Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
6.47
0.00
0.00%
Follow SVA
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
11,072.54 | 10,577.31 | 9,935.26 | 6,199.50 |
Receivables |
500.44 | 404.72 | 321.79 | 294.31 | |
Inventory |
182.74 | 153.52 | 109.14 | 106.61 | |
Total current assets |
11,769.03 | 11,148.28 | 10,376.79 | 6,624.41 | |
Property, Plant, Equpment (Net) |
1,058.96 | 934.61 | 858.56 | 697.07 | |
Long-Term Investments |
657.77 | 681.35 | 498.79 | 576.09 | |
Long-term receivables |
— | — | 34.28 | 19.28 | |
Goodwill and Intangible Assets (Total) |
8.75 | 7.84 | 86.59 | 92.21 | |
Long Term Assets (Tax, Deferred) |
98.69 | 32.80 | 34.56 | 37.85 | |
Long-term assets (Other) |
84.14 | 76.71 | 82.69 | 82.67 | |
Total non-current assets |
1,955.99 | 1,748.66 | 1,610.28 | 1,514.38 | |
Total Assets |
13,725.01 | 12,896.94 | 11,987.07 | 8,138.79 | |
Notes Payable |
4.16 | — | — | — | |
Accounts Payable |
819.53 | 641.58 | 590.13 | 250.23 | |
Dividends Payable |
15.15 | 119.37 | 3,958.19 | 657.18 | |
Current Part of Debt |
201.12 | 179.35 | 214.96 | 148.05 | |
Current Part of Taxes to Pay |
— | 28.72 | 221.91 | 16.69 | |
Current Revenue (Deferred) |
139.55 | 6.17 | 12.01 | 9.43 | |
Other current liabilities |
4.13 | 0.81 | 1.74 | 5.34 | |
Total current liabilities |
1,189.63 | 978.45 | 5,001.41 | 1,091.16 | |
Long Term Debt (Total) |
10.99 | 130.32 | 233.06 | 233.12 | |
Non-current Revenue (Deferred) |
— | 0.20 | — | — | |
Long Term Tax Liability (Deferred) |
239.03 | 262.17 | 392.04 | 335.87 | |
Non-current Liabilities (Other) |
7.18 | 6.41 | 4.38 | 6.11 | |
Total non-current liabilities |
298.13 | 411.49 | 642.18 | 582.73 | |
Total liabilities |
1,487.75 | 1,389.94 | 5,643.59 | 1,673.88 | |
Additional Paid In Capital |
541.26 | 541.26 | 550.17 | 550.17 | |
Preferred Stock (Total) |
0.02 | 0.02 | — | — | |
Common Stock (Net) |
0.10 | 0.10 | 0.07 | 0.07 | |
Retained Earnings |
7,239.95 | 7,107.64 | 2,858.50 | 2,755.71 | |
Shareholders Equity (Other) |
1,538.01 | 1,539.58 | 1,581.47 | 1,586.01 | |
Common Equity (Total) |
12,237.24 | 11,506.98 | 6,343.48 | 6,464.90 | |
Shareholders Equity (Total) |
12,237.26 | 11,507.00 | 6,343.48 | 6,464.90 | |
Shareholders Equity and Liabilities (Total) |
13,725.01 | 12,896.94 | 11,987.07 | 8,138.79 | |
Shareholders Equity (Tangible) |
12,228.50 | 11,499.15 | 6,256.89 | 6,372.69 | |
Net Debt |
(10,860.43) | (10,267.64) | (9,487.24) | (5,818.33) | |
Total Debt |
212.11 | 309.67 | 448.02 | 381.17 |
In millions of $ except per-share values · columns are period end dates